CXCR6 Antibody

What is CXCR6 and what are its primary functions?

CXCR6 (CD186) is a receptor for the C-X-C chemokine CXCL16 and functions as a G-protein coupled receptor. It serves as a coreceptor for certain strains of HIV-2, m-tropic HIV-1, and SIVs . More importantly, CXCR6 plays critical roles in T cell trafficking and function, particularly for CD8+ T cells in tumor microenvironments and CD4+ T cells in inflammatory conditions. CXCR6 contains a unique DRF motif instead of the typical DRY motif found in other chemokine receptors, which affects its signaling properties and chemotactic function .

The receptor is primarily expressed on specific T cell populations and marks functionally distinct subsets with heightened effector capabilities in different contexts. Research suggests CXCR6 serves as a biomarker for immunocompetent T cells in anti-tumor immunity and for pathogenic T cells in autoimmune and inflammatory diseases .

What applications are CXCR6 antibodies commonly used for?

CXCR6 antibodies are utilized in multiple experimental techniques including:

• Western blotting (WB): For detecting CXCR6 protein in tissue lysates with reported band sizes of approximately 39-44 kDa

• Immunofluorescence (IF): For visualizing CXCR6 expression in tissue sections, such as human spleen tissue

• Immunohistochemistry (IHC-P): For detecting CXCR6 in formalin-fixed, paraffin-embedded tissue samples

• Flow cytometry: For identifying and isolating CXCR6-positive cell populations

• In vivo studies: CXCR6 antibodies have been used for depletion of specific T cell populations in animal models of autoimmune disease and cancer

How should researchers validate the specificity of CXCR6 antibodies?

Validation of CXCR6 antibodies should include:

• Peptide competition assays: As demonstrated in western blot results where the signal disappears in the presence of the immunizing peptide

• Use of appropriate positive controls: Human spleen tissue shows reliable CXCR6 expression

• Confirming expected band size: The predicted molecular weight is 39 kDa, though observed bands may appear at 44 kDa due to post-translational modifications

• Comparison with CXCR6 knockout models: Using tissues from CXCR6-deficient mice (Cxcr6^gfp/gfp or Cxcr6^-/-) as negative controls

• Cross-validation with multiple detection methods: Comparing results from western blotting, immunofluorescence, and flow cytometry

How does CXCR6 expression on T cells correlate with their functional properties in different disease contexts?

The relationship between CXCR6 expression and T cell functionality varies significantly depending on the disease context:

In cancer: CXCR6+CD8+ T cells within tumors demonstrate enhanced immunocompetence compared to their CXCR6- counterparts. These cells show greater antitumor activity and respond more effectively to immune checkpoint blockade therapy . Studies using chimeric models with specific deficiency of CXCR6 in CD8+ T cells revealed impaired antitumor activity, suggesting CXCR6 is critical for optimal CD8+ T cell function in the tumor microenvironment .

In autoimmune diseases: CXCR6+ CD4+ T cells represent terminally differentiated effector cells with pathogenic properties. They proliferate rapidly and produce multiple inflammatory cytokines, including IFN-γ, IL-17, and GM-CSF . Depletion of CXCR6+ CD4+ T cells using anti-CXCR6 monoclonal antibodies significantly reduced disease severity in experimental autoimmune encephalomyelitis (EAE) models .

Interestingly, while CXCR6 marks highly pathogenic T cells in autoimmune settings, the same marker identifies immunocompetent T cells important for antitumor responses, highlighting the context-dependent nature of CXCR6 function .

What mechanisms regulate CXCR6 expression on T cells in tumor microenvironments?

The induction of CXCR6 on T cells in tumor contexts involves multiple mechanisms:

• Tumor tissue-intrinsic factors: Research demonstrates that the tumor microenvironment itself, rather than just CXCL16-mediated chemotaxis, induces CXCR6 expression on CD8+ T cells. This was demonstrated in experiments where tumor tissues could induce CXCR6 expression on naive T cells even when separated by a transwell system .

• T cell activation: CXCR6 expression increases following T cell activation with CD3/CD28 stimulation in the presence of tumor cells or tumor-derived factors .

• Temporal dynamics: In experimental models, CXCR6+CD8+ T cells could be detected at days 2, 4, and 7 after exposure to tumor cells, indicating a progressive induction pattern .

• Antigen specificity: Induced CXCR6+CD8+ T cells demonstrate tumor antigen specificity, suggesting that antigen recognition plays a role in CXCR6 upregulation .

This induction of CXCR6 on T cells by tumor tissue suggests that CXCR6 could serve as a biomarker for effective antitumor T cells and potentially as a selection marker before adoptive cell therapy (ACT) .

How do CXCR6 structural features impact its signaling and functional properties?

CXCR6 contains several unique structural features that distinguish it from other chemokine receptors:

These structural peculiarities help explain the specialized functional roles of CXCR6 beyond simple chemotaxis, potentially contributing to its context-dependent effects in different disease states.

What are the optimal protocols for detecting CXCR6 expression in tissue samples?

Based on published research protocols, optimal detection of CXCR6 in tissue samples includes:

Immunofluorescence protocol:

• Use antibody concentrations of approximately 20 μg/ml for human spleen tissue sections

• Include DAPI staining for nuclear visualization

• Look for membrane/cytoplasmic CXCR6 staining pattern (green) in lymphoid-rich areas

Immunohistochemistry protocol:

• Use antibody concentrations of approximately 20 μg/ml for human spleen tissues

• Include appropriate blocking steps to reduce background

• Optimize antigen retrieval methods for formalin-fixed, paraffin-embedded samples

Western blotting protocol:

• Use antibody dilutions of approximately 1/500

• Include peptide competition controls to verify specificity

• Expect bands at approximately 44 kDa (predicted size: 39 kDa)

• Human spleen tissue lysate serves as a reliable positive control

How can researchers effectively isolate and study CXCR6+ T cell populations?

To isolate and characterize CXCR6+ T cells:

• Flow cytometry-based isolation:

  • Use fluorescently-labeled anti-CXCR6 antibodies in combination with other T cell markers (CD4, CD8)

  • Apply fluorescence-activated cell sorting (FACS) to separate CXCR6+ and CXCR6- populations for functional studies

• Genetic approaches:

  • Utilize CXCR6-GFP reporter mice (Cxcr6^gfp/gfp) where GFP expression marks CXCR6+ cells

  • Create bone marrow chimeras to study cell-specific CXCR6 functions:

    • Mix bone marrow from Cxcr6^-/- Cd8^-/- mice and from Cxcr6^-/- or wild-type mice (7:3 ratio)

    • Transfer into lethally irradiated recipients (5×10^6 cells per mouse)

• In vitro induction system:

  • Mix tumor cells and naive T cells (1:100 ratio) in 24-well plates

  • Add IL-2 (10 ng/mL) and CD3/CD28 stimulating antibodies (5 μg/mL each)

  • For tumor tissue-mediated induction, use transwell systems with shredded tumor tissues in upper wells and naive T cells in lower wells

• Adoptive transfer experiments:

  • Isolate CXCR6+CD8+ T cells by FACS

  • Transfer 5×10^6 cells intravenously into tumor-bearing mice

  • Monitor tumor progression to assess functional effects

What experimental controls are essential when studying CXCR6 function in disease models?

Critical experimental controls include:

• Genetic controls:

  • CXCR6-deficient mice (Cxcr6^-/-) for loss-of-function studies

  • Wild-type littermates as positive controls

  • For antigen-specific studies, compare Cxcr6^-/- OT-I and wild-type OT-I mice

• Antibody specificity controls:

  • Include isotype controls for antibody treatments (e.g., when using anti-PD-1 or anti-CXCR6 antibodies)

  • Use peptide competition assays to validate antibody specificity

• Adoptive transfer controls:

  • Compare CXCR6+ and CXCR6- T cell populations from the same donor

  • For antigen-specific studies, use OVA-specific T cells (OT-I) with and without CXCR6 expression

• Chimeric models:

  • Create bone marrow chimeras with specific CXCR6 deficiency in CD8+ T cells

  • Use mixed chimeras with CD45.1/CD45.2 markers to track cells from different donors

• Treatment controls:

  • For anti-PD-1 therapy experiments, include isotype antibody controls

  • When testing combination therapies, include single-agent treatment groups

How might CXCR6-targeted approaches be developed for immunotherapy?

CXCR6-targeted therapeutic approaches could be developed based on disease-specific contexts:

For autoimmune diseases:

• Depleting antibodies: Anti-CXCR6 monoclonal antibodies could selectively deplete pathogenic CXCR6+ T cells, as demonstrated in EAE models where this approach dramatically reverted disease

• Receptor antagonists: Small molecules or peptides that block CXCR6-CXCL16 interactions could inhibit pathogenic T cell trafficking and function

• Targeted immunosuppression: Delivering immunosuppressive drugs specifically to CXCR6+ pathogenic T cells could reduce global immunosuppression

For cancer immunotherapy:

• Enrichment strategies: Selecting CXCR6+CD8+ T cells for adoptive cell therapy could enhance antitumor efficacy

• Combination approaches: CXCR6+CD8+ T cells showed enhanced responses to anti-PD-1 therapy, suggesting CXCR6 could serve as a biomarker for checkpoint inhibitor responsiveness

• In vitro induction: Protocols to induce CXCR6 expression on tumor-specific T cells before adoptive transfer could improve therapeutic outcomes

The opposing roles of CXCR6 in autoimmunity (pathogenic) versus cancer (protective) highlight the need for context-specific therapeutic approaches.

What are the critical contradictions and knowledge gaps in current CXCR6 research?

Several important contradictions and knowledge gaps exist:

• Context-dependent roles: CXCR6 marks pathogenic T cells in autoimmunity but immunocompetent T cells in tumors. The molecular mechanisms underlying these opposing functions remain poorly understood .

• Dispensability paradox: CXCR6 appears dispensable in some autoimmune models but critical in others. For instance, CXCR6-knockout mice showed reduced severity in some autoimmune models, while CXCR6 depletion with antibodies significantly improved EAE .

• Species differences: In human multiple sclerosis, the major T cells in brain lesions are CXCR6+CD8+ T cells, whereas in mouse EAE models, CXCR6+CD4+ T cells are the primary pathogenic population . These species differences complicate translational research.

• Induction mechanisms: While tumor tissues can induce CXCR6 expression on T cells, the specific factors and signaling pathways responsible remain largely unknown .

• CXCL16/CXCR6 chemotaxis vs. other functions: The DRF motif in CXCR6 impairs its chemotactic function compared to other chemokine receptors, suggesting CXCR6 may have important non-chemotactic functions that require further investigation .

• Therapeutic targeting: Whether targeting CXCR6 provides advantages over current immunotherapies, and how to best target it in different disease contexts, remains to be determined.

How does CXCR6 expression correlate with response to immune checkpoint inhibitors?

Research indicates significant relationships between CXCR6 expression and immune checkpoint inhibitor efficacy:

• Enhanced responsiveness: CXCR6+CD8+ T cells show greater responsiveness to anti-PD-1 therapy compared to their CXCR6- counterparts .

• Predictive biomarker potential: In mouse models, CXCR6-deficient mice (Cxcr6^-/-) responded poorly to anti-PD-1 treatment, suggesting CXCR6 expression may predict checkpoint inhibitor efficacy .

• Combination approaches: Induced CXCR6+CD8+ T cells enhanced the effect of anti-PD-1 blockade in retarding tumor progression, indicating potential synergy between CXCR6+ cell-based therapies and checkpoint inhibition .

• Mechanistic considerations:

  • CXCR6+CD8+ T cells are more immunocompetent within the tumor microenvironment

  • These cells likely express inhibitory receptors like PD-1 that, when blocked, allow their enhanced effector functions to emerge

  • The antigen specificity of CXCR6+CD8+ T cells suggests they recognize tumor antigens and can be functionally reinvigorated by checkpoint blockade

These findings suggest CXCR6 could serve as both a predictive biomarker for checkpoint inhibitor response and a potential target for combination immunotherapy approaches.

What criteria should researchers consider when selecting CXCR6 antibodies for specific applications?

When selecting CXCR6 antibodies, researchers should consider:

• Application-specific validation:

  • For Western blotting: Confirm detection of the expected 39-44 kDa band with appropriate controls

  • For immunofluorescence/IHC: Verify specific staining patterns in known positive tissues (e.g., human spleen)

  • For flow cytometry: Ensure clear separation of positive and negative populations

• Species reactivity:

  • Confirm antibody reactivity with the target species (human, mouse, etc.)

  • For cross-species studies, select antibodies validated across multiple species

  • Consider homology between species for the immunogen sequence

• Immunogen information:

  • Preference for antibodies raised against physiologically relevant epitopes

  • Antibodies targeting the N-terminal region (aa 1-50) have shown good specificity

  • Consider whether the immunogen is a synthetic peptide, recombinant protein, or cell-derived material

• Experimental validation status:

  • Review available data on antibody performance in your specific application

  • Consider antibodies with published validation in multiple applications

  • Evaluate citation records for antibodies in similar research contexts

• Clone type considerations:

  • Monoclonal antibodies offer consistent lot-to-lot reproducibility

  • Polyclonal antibodies may provide higher sensitivity by recognizing multiple epitopes

  • For depletion studies, select antibodies with demonstrated efficacy (e.g., clone 19A5)

How can researchers troubleshoot common issues with CXCR6 antibody staining?

Common troubleshooting approaches include:

• Weak or absent signal in Western blotting:

  • Increase antibody concentration (try 1/250 if 1/500 is insufficient)

  • Extend primary antibody incubation time or temperature

  • Enhance protein loading (50-100 μg of total protein)

  • Use human spleen tissue as a positive control

  • Verify sample preparation preserves membrane proteins

• High background in immunofluorescence/IHC:

  • Optimize blocking conditions (duration, blocking agent)

  • Reduce primary antibody concentration below 20 μg/ml

  • Include additional washing steps

  • Use peptide competition controls to confirm specificity

• Poor separation in flow cytometry:

  • Optimize antibody titration

  • Ensure proper cell preparation (fresh samples, appropriate buffers)

  • Include FMO (fluorescence minus one) controls

  • Use CXCR6-deficient cells as negative controls

• Inconsistent results between experiments:

  • Standardize protocols across experiments

  • Use consistent antibody lots when possible

  • Include positive and negative controls in each experiment

  • Document exact experimental conditions for reproducibility